David Ricks, CEO, Eli Lilly.
Scott Mlyn | CNBC
Eli Lilly's (LLY) attempt to receive accelerated regulatory approval for its Alzheimer's drug donanemab has been rejected. While the setback hit the stock Friday, it's not rattling our long-term belief in the company.